This is a pivotal moment for the food industry. Noting that 12% of the US population has tried the drugs, with 6% actively using them, Harold Schmitz at VC firm The March Group said the Ozempic era is helping to rejuvenate the foodtech space, which is now very much alive. Courtney McHugh, chief commercial officer at Amplifye, a UC Davis spinout with an enzyme that helps the body digest protein more effectively, added: Theres an entire secondary market that can come from any breakthrough technology. This is only the first generation of GLP-1 drugs and therefore the first generation of secondary markets, observed McHugh, who said GLP-1 drugs are driving interest in products that solve for energy levels, nutrient deficiencies, and gut issues. They are also prompting renewed interest in protein quality as well as quantity, she claimed
For L-carnitine, this might include plasma carnitine levels, fatty acid oxidation rates, or ATP production
Avoid Overdosing: Stick to the recommended dosage to avoid potential side effects like mild gastrointestinal discomfort
C.DiasS
Post-Marketing Surveillance and Real-World Data Integration Programs like U.S
